Terminated PHASE3 INTERVENTIONAL 2-arm NCT00411801

Safety and Efficacy Study to Compare Uniplas With Cryosupernatant Plasma in Thrombotic Thrombocytopenic Purpura (TTP)

A Blinded Non-inferiority Study to Compare Uniplas With Cryosupernatant Plasma in Thrombotic Thrombocytopenic Purpura (TTP)

Sponsor: Octapharma

Conditions Thrombotic Thrombocytopenic Purpura (TTP)

Interventions Cryosupernatant plasma Uniplas

Updated 7 times since 2017 Last updated: Jun 19, 2017 Started: May 31, 2007 Primary completion: Feb 29, 2008 Completion: Feb 29, 2008

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Terminated

Insufficient enrollment

Other terminated trials from Octapharma

See all terminations from Octapharma

This PHASE3 trial investigates Thrombotic Thrombocytopenic Purpura (TTP) and is currently terminated or withdrawn. Octapharma leads this study, which shows 7 recorded versions since 2007 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

Change History

7 versions recorded

Sep 2024 — Present [monthly]

Terminated PHASE3
Jul 2024 — Sep 2024 [monthly]

Terminated PHASE3
Apr 2022 — Jul 2024 [monthly]

Terminated PHASE3
Jan 2021 — Apr 2022 [monthly]

Terminated PHASE3
Jun 2018 — Jan 2021 [monthly]

Terminated PHASE3

▶ Show 2 earlier versions

Feb 2017 — Jun 2018 [monthly]

Terminated PHASE3
Jan 2017 — Feb 2017 [monthly]

Terminated PHASE3

First recorded

May 2007

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Octapharma

Data source: Octapharma

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Centreville, United States